Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia.
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Friedreich's ataxia
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 15 Mar 2017 Phase changed from 0 to early phase 1.
- 06 Jul 2016 Status changed from not yet recruiting to recruiting.